All High-Throughput Screening (HTS) articles – Page 10
-
WhitepaperGuide: Screening biologic candidates with nanoDSF
Read this guide about nanoDSF for high-resolution measurements of thermal stability parameters, common CQAs for biologics developability assessment.
-
NewsNew test promises better detection of elusive cervical cancers
Researchers have developed a novel test capable of detecting a form of cervical cancer that frequently eludes detection through traditional Pap tests.
-
WhitepaperInfographic: Biologics stability in early development
Stability attributes of biologic candidates are evaluated during early development workflows. Learn how to measure them with biophysical techniques.
-
WebinarTurning Plans into Reality: Real Examples of Custom Automation Projects
Watch our industry experts to learn about the tangible benefits and best practice of custom flow cytometry automation projects. You’ll discover how to reduce your challenges implementing tailored automation, controlling the quality of the data produced and improving the reliability of your data acquisition.
-
WebinarSH2 domains as a target class in cancer and inflammation
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
-
WebinarBridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics
The webinar will explore primary concerns in drug discovery development and why drugs fail.
-
News
Rare cause of hereditary cancer missed in younger patients
US investigators find that some cases of Lynch syndrome, the most common hereditary cancer condition, are missed in younger patients under current screening guidelines.
-
WhitepaperCase study: Mitochondrial toxicity in drug discovery and development
The Agilent Seahorse XF assay platform has opened new avenues for examining mitochondrial health in a timely and effective manner.
-
WhitepaperApplication note: Novel screening tools for TMEM175 drug discovery
In this article, learn about how TMEM175 is an exciting new target in normal physiology and in disease. Also, read about how the use of biomarkers in Alzheimer’s drug development will address many of the challenges currently encountered.
-
WebinarCardiac and vascular safety liabilities using totality of evidence approach
US-FDA recommend integration of both preclinical (S7B) and clinical (E14) data to improve risk assessment, reduce reliance on TQT clinical studies, streamlined drug-development, simplified decision-making processes, effective risk-communication.
-
ArticleDrug Target Review Screening eBook 2023
In this eBook, uncover the transformative potential of AI/ML in single-cell technologies and gain insights into disease progression.
-
ArticleDrug Target Review - Issue 2 2023
A new Drug Target Review issue is now ready to download! This issue features articles on cell and gene therapy, imaging and screening.
-
Whitepaperebook: Choosing the right assay for PARP
This eBook describes different types of assays used to evaluate PARP activity and screening for specific inhibitors.
-
WhitepaperBrochure: Overcome roadblocks in your PROTAC characterizations with Dianthus
Learn how Dianthus resolves common challenges you face during the characterization of PROTAC binary and ternary complexes and the determination of cooperativity.
-
VideoVideo: Using luciferase reporter cell lines for HTS readouts
This video reviews the uses and advantages of reporter cell lines in the context of cellular research and drug discovery.
-
Company profileRevvity
Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure.
-
Whitepaperebook: TR-FRET assay kits simplify & accelerate drug discovery
This ebook provides basic principles of the TR-FRET technology and shows examples of how assay design can drive drug discovery.
-
Articleebook: Never Miss A Hit - Unleash Your Drug Discovery With A Label-Free Playlist
Get ready to dive into the cutting-edge world of hit-to-lead drug discovery. Look no further than our latest FREE ebook, which explores label-free HTL technologies. Featuring the latest research from leading academics and pharmaceutical companies, including GlaxoSmithKline, Rosalind Franklin Institute and Francis Crick Institute.
-
VideoWebinar: The Role of Neuronal Metabolism in Early Drug Discovery
Learning about the mitochondrial role in a neurodegenerative disorder.
-
ArticleDrug Target Review Assays ebook 2023
Download your FREE ebook on assays, featuring articles from experts who write about developments in screening and the importance of performing comprehensive multiplex spatial and temporal profiling of drugs in pre-clinical research.